James Galeota, Merck
S
James Galeota
SVP, General Manager, Diabetes and Obesity, Merck
BIGGEST ACCOMPLISHMENT: Establishing Merck's diabetes franchise
ADMIRES: Those that can help others live up to their potential
On stopping the silos:
Commercialization is not about discreet disciplines. At Merck, I have been able to see into different parts of the company and see the value that can be created when all the divisions are synchronized—when you have teams that are aligned around objectives, sharing the same measures of success, holding each other accountable, and working together to solve complex problems.
James Galeota
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Novo Nordisk, The United Laboratories Ink Exclusive License Agreement for Triple Receptor Agonist
March 25th 2025Under terms of the license agreement, Novo Nordisk will acquire the rights to develop and commercialize UBT251 outside of China for obesity and type 2 diabetes for an upfront payment of $200 million.
